Bahrami Pegah, Aromolaran Kelly A, Aromolaran Ademuyiwa S
Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, 95 S 2000 E, Salt Lake City, UT 84112, USA.
Department of Surgery, Division of Cardiothoracic Surgery, Nutrition & Integrative Physiology, Biochemistry & Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Int J Mol Sci. 2024 Dec 14;25(24):13423. doi: 10.3390/ijms252413423.
Heart failure with preserved ejection fraction (HFpEF) is increasing at an alarming rate worldwide, with limited effective therapeutic interventions in patients. Sudden cardiac death (SCD) and ventricular arrhythmias present substantial risks for the prognosis of these patients. Obesity is a risk factor for HFpEF and life-threatening arrhythmias. Obesity and its associated metabolic dysregulation, leading to metabolic syndrome, are an epidemic that poses a significant public health problem. More than one-third of the world population is overweight or obese, leading to an enhanced risk of incidence and mortality due to cardiovascular disease (CVD). Obesity predisposes patients to atrial fibrillation and ventricular and supraventricular arrhythmias-conditions that are caused by dysfunction in the electrical activity of the heart. To date, current therapeutic options for the cardiomyopathy of obesity are limited, suggesting that there is considerable room for the development of therapeutic interventions with novel mechanisms of action that will help normalize sinus rhythms in obese patients. Emerging candidates for modulation by obesity are cardiac ion channels and Ca-handling proteins. However, the underlying molecular mechanisms of the impact of obesity on these channels and Ca-handling proteins remain incompletely understood. Obesity is marked by the accumulation of adipose tissue, which is associated with a variety of adverse adaptations, including dyslipidemia (or abnormal systemic levels of free fatty acids), increased secretion of proinflammatory cytokines, fibrosis, hyperglycemia, and insulin resistance, which cause electrical remodeling and, thus, predispose patients to arrhythmias. Furthermore, adipose tissue is also associated with the accumulation of subcutaneous and visceral fat, which is marked by distinct signaling mechanisms. Thus, there may also be functional differences in the effects of the regional distribution of fat deposits on ion channel/Ca-handling protein expression. Evaluating alterations in their functional expression in obesity will lead to progress in the knowledge of the mechanisms responsible for obesity-related arrhythmias. These advances are likely to reveal new targets for pharmacological modulation. Understanding how obesity and related mechanisms lead to cardiac electrical remodeling is likely to have a significant medical and economic impact. Nevertheless, substantial knowledge gaps remain regarding HFpEF treatment, requiring further investigations to identify potential therapeutic targets. The objective of this study is to review cardiac ion channel/Ca-handling protein remodeling in the predisposition to metabolic HFpEF and arrhythmias. This review further highlights interleukin-6 (IL-6) as a potential target, cardiac bridging integrator 1 (cBIN1) as a promising gene therapy agent, and leukotriene B4 (LTB4) as an underappreciated pathway in future HFpEF management.
射血分数保留的心力衰竭(HFpEF)在全球范围内正以惊人的速度增加,而针对这类患者的有效治疗干预措施有限。心源性猝死(SCD)和室性心律失常给这些患者的预后带来了重大风险。肥胖是HFpEF和危及生命的心律失常的一个危险因素。肥胖及其相关的代谢失调会导致代谢综合征,这是一种流行病,构成了重大的公共卫生问题。世界上超过三分之一的人口超重或肥胖,这导致心血管疾病(CVD)的发病率和死亡率风险增加。肥胖使患者易患心房颤动以及室性和室上性心律失常,这些病症是由心脏电活动功能障碍引起的。迄今为止,针对肥胖性心肌病的现有治疗选择有限,这表明具有新作用机制的治疗干预措施仍有很大的发展空间,这些措施将有助于肥胖患者恢复窦性心律。肥胖可能影响的新候选对象是心脏离子通道和钙处理蛋白。然而,肥胖对这些通道和钙处理蛋白影响的潜在分子机制仍未完全了解。肥胖的特征是脂肪组织的积累,这与多种不良适应性变化有关,包括血脂异常(或游离脂肪酸的全身水平异常)、促炎细胞因子分泌增加、纤维化、高血糖和胰岛素抵抗,这些都会导致电重构,从而使患者易患心律失常。此外,脂肪组织还与皮下和内脏脂肪的积累有关,其具有不同的信号传导机制。因此,脂肪沉积的区域分布对离子通道/钙处理蛋白表达的影响可能也存在功能差异。评估肥胖状态下它们功能表达的变化将推动对肥胖相关心律失常机制的认识取得进展。这些进展可能会揭示新的药物调节靶点。了解肥胖及相关机制如何导致心脏电重构可能会产生重大的医学和经济影响。然而,在HFpEF治疗方面仍存在重大知识空白,需要进一步研究以确定潜在的治疗靶点。本研究的目的是综述代谢性HFpEF和心律失常易感性中心脏离子通道/钙处理蛋白的重塑。本综述进一步强调白细胞介素-6(IL-6)作为一个潜在靶点、心脏桥连整合素1(cBIN1)作为一种有前景的基因治疗药物以及白三烯B4(LTB4)作为未来HFpEF管理中一个未被充分认识的途径。